mRNA Synthesis Raw Materials Industry
The global mRNA synthesis raw materials market was valued at USD 1.72 billion in 2023, with a projected compound annual growth rate (CAGR) of 2.85% from 2024 to 2030. mRNA synthesis occurs through the process of transcription within the nucleus, using a DNA nucleotide sequence as a template. This process involves several stages, including initiation, elongation, editing, and termination. mRNA synthesis has broad applications in fields such as drug discovery, vaccine development, and therapeutic manufacturing. RNA-based vaccines, in particular, offer notable benefits including better immunogenicity, higher efficiency, and faster production times. These factors, along with growing academic and industrial interest in mRNA technology and increasing funding for research, are driving the market's growth.
A significant milestone in mRNA vaccine development occurred in March 2020, when the National Institute of Allergy & Infectious Diseases (NIAID) and Moderna, Inc. co-developed mRNA-1273, a vaccine with 94.1% efficacy in preventing symptomatic COVID-19. In December 2020, this vaccine received emergency use authorization from the U.S. Food & Drug Administration (FDA), leading to a dramatic increase in the use of mRNA vaccines during the pandemic. This surge in demand showcased the potential of mRNA technology, significantly boosting market growth.
In recent years, RNA research centers have been established at several prestigious institutions to explore the therapeutic potential of RNA, particularly in vitro transcribed (IVT) mRNA. Examples include the Yale Center for RNA Science and Medicine, the RNA Institute at the University of Albany, and the RNA Therapeutic Institute at the University of Massachusetts. Additionally, university spin-off companies, backed by substantial venture capital investments, have accelerated the preclinical and clinical development of mRNA-based therapeutics. Companies such as Argos Medicines, Factor Bioscience, CureVac, Ethris, BioNTech, Moderna, eTheRNA, and Onkaido have been at the forefront of these advancements. As academic and industrial interest in mRNA technology continues to grow, the demand for mRNA synthesis raw materials is expected to increase, further propelling market growth.
Gather more insights about the market drivers, restrains and growth of the mRNA Synthesis Raw Materials Market
Application Insights
In 2023, the vaccine production segment led the global industry, holding the largest revenue share.
- This leadership can be attributed to the faster production rate of mRNA vaccines compared to traditional vaccines, which rely on cell-culture-based production that often faces higher failure rates.
- Advancements in mRNA technology have paved the way for faster and more flexible vaccine production, enabling manufacturers to scale up capacity to meet growing global demands.
- The rising need for vaccines has opened up opportunities for building flexible vaccine manufacturing facilities worldwide.
- For instance, Australia began constructing a large-scale mRNA manufacturing facility in December 2022, expected to become operational in 2024.
- This facility aims to produce up to 100 million doses annually for respiratory diseases such as influenza and respiratory syncytial virus (RSV).
- The escalating demand for vaccines subsequently drives the need for raw materials, which boosts overall market growth.
The therapeutics production segment is anticipated to grow at a significant CAGR of 2.65% from 2024 to 2030, primarily due to the rising prevalence of chronic and infectious diseases.
- According to the World Health Organization (WHO), approximately 10.6 million people worldwide were diagnosed with tuberculosis (TB) in 2021, including 1.2 million children, 6 million men, and 3.4 million women.
- mRNA-based therapeutics are emerging as promising solutions for both treatment and prevention, offering innovative approaches to tackling a variety of diseases.
- Increasing clinical trials and in vivo models for mRNA-based therapeutics are helping to expand research and development, driving revenue growth in this segment.
Order a free sample PDF of the mRNA Synthesis Raw Materials Market Intelligence Study, published by Grand View Research.
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
